Study: A092204: A PHASE II STUDY OF CABOZANTINIB IN COMBINATION WITH CEMIPLIMAB (REGN2810) (CABO-CEMIPLIMAB (REGN2810)) VERSUS CABOZANTINIB ALONE IN ADOLESCENTS AND ADULTS WITH ADVANCED ADRENOCORTICAL CANCER
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 5 to 7 business days.
Please understand that:
Thanks again. Volunteers such as yourself are at the core of our work.